PURAPHARM (01498) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of HK$172 million, representing a 17.02% decrease compared to the same period last year. The loss attributable to owners of the parent company reached HK$21.806 million, an increase of 16.7% year-on-year. Basic loss per share was HK$5.52 cents.

According to the announcement, the revenue decline was primarily attributed to the slowdown in Hong Kong consumption and intense market competition, as well as the group's continued strategy to de-emphasize hospital channels in China's concentrated traditional Chinese medicine formula granules market.